STX-0119
Based on 2 publication(s) in Google Scholar
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.
For research use only. We do not sell to patients.
- Purity: 98.40%
- CAS No.: 851095-32-4
- Formula: C22H14N4O3
- Molecular Weight:382.37
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) STX-0119
More
Biological Activity
|
STAT3 74 μM (IC50, STAT3 transcription) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
16.2 μM
Compound: Cpd II
|
Cytotoxicity against human A-375 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTS assay
Cytotoxicity against human A-375 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTS assay
|
[PMID: 31784187] |
| A549 | IC50 |
11.59 μM
Compound: 1; STX-119
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 34000483] |
| HeLa | IC50 |
74 μM
Compound: 1c, STX-0119
|
Inhibition of STAT3 transcriptional activity in human HeLa cells by luciferase reporter gene assay
Inhibition of STAT3 transcriptional activity in human HeLa cells by luciferase reporter gene assay
|
[PMID: 24900220] |
| HFF | IC50 |
72.2 μM
Compound: Cpd II
|
Cytotoxicity against HFF assessed as inhibition of cell proliferation by MTS assay
Cytotoxicity against HFF assessed as inhibition of cell proliferation by MTS assay
|
[PMID: 31784187] |
| MCF-10A | IC50 |
33.4 μM
Compound: Cpd II
|
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation by MTS assay
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation by MTS assay
|
[PMID: 31784187] |
| MDA-MB-231 | IC50 |
18.25 μM
Compound: 1; STX-119
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 34000483] |
| MGC-803 | IC50 |
7.43 μM
Compound: 1; STX-119
|
Antiproliferative activity against human MGC-803 cells
Antiproliferative activity against human MGC-803 cells
|
[PMID: 34000483] |
STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells[1].
STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468 cells
-
Concentration:10, 20 and 50 μM
-
Incubation Time:24 h
-
Result:Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.
The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model[1]
-
Dosage:160 mg/kg
-
Administration:Oral gavage, daily for 4 days
-
Result:Suppressed the growth of SCC-3 cells significantly on the fourth day.
Chemical Information
-
CAS No. 851095-32-4
-
Appearance Solid
-
Molecular Weight 382.37
-
Formula C22H14N4O3
-
Color White to light yellow
-
SMILES
O=C(C1=CC(C2=CC=CC=C2)=NC3=C1C=CC=C3)NC4=NN=C(C5=CC=CO5)O4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Selective STAT3 inhibitor STX-0119 alleviates osteoarthritis progression by modulating the STAT3/PPARγ signaling pathway. [Abstract]2024 Jul 10:116420. PMID: 38996934 -
Solvent & Solubility
DMSO : 13.33 mg/mL (34.86 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6153 mL | 13.0763 mL | 26.1527 mL | 65.3817 mL |
| 5 mM | 0.5231 mL | 2.6153 mL | 5.2305 mL | 13.0763 mL | |
| 10 mM | 0.2615 mL | 1.3076 mL | 2.6153 mL | 6.5382 mL | |
| 15 mM | 0.1744 mL | 0.8718 mL | 1.7435 mL | 4.3588 mL | |
| 20 mM | 0.1308 mL | 0.6538 mL | 1.3076 mL | 3.2691 mL | |
| 25 mM | 0.1046 mL | 0.5231 mL | 1.0461 mL | 2.6153 mL | |
| 30 mM | 0.0872 mL | 0.4359 mL | 0.8718 mL | 2.1794 mL |
STX-0119 Related Classifications
HY-103692 Related Classifications
Powered by Bioz